CD79A and IgA glomerulonephritis: Ionis has partnered with Roche todevelop a ligand-conjugated ASO therapeutic, IONIS-FB-LRx, which targetsFB to reduce the production of IgA and alleviate the symptoms of IgAnephropathy (Table 8).151